Availability of Veterinary Medicines. Availability of Veterinary Medicines. Using the Cascade and Essential List for Equidae

Similar documents
Cascade. Guide for veterinarians if NO authorised medicinal product is available. Federation of Veterinarians of Europe

This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents

This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents

SUMMARY OF PRODUCT CHARACTERISTICS

Workshop on Strengthening livestock health and Veterinary Services. Kiev, 2-3 November 2010 TAIEX, AGR 42266

Further memorandum submitted by the Department for Environment, Food and Rural Affairs

Having regard to the Treaty establishing the European Community, and in particular Article 152(4)(b) thereof,

Knowledge list Avian/Exotic Pharmacology and Commonly Used Drugs

2006 No. 755 FOOD. The Animals and Animal Products (Examination for Residues and Maximum Residue Limits) (Amendment) Regulations 2006

DIRECTIVE 2001/82/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 November 2001 on the Community code relating to veterinary medicinal products

HEALTH & CONSUMERS DIRECTORATE-GENERAL

L 210/36 Official Journal of the European Union DECISIONS COMMISSION

GREYHOUND RACING VICTORIA PROHIBITED SUBSTANCE PENALTY GUIDELINE AND RELEVANT INFORMATION PERTAINING TO PROHIBITED SUBSTANCE OFFENCES

Legislation on Veterinary Medicinal Products (VMPs) and legal status of relevant VMPs for anesthesia of finfish

No July 2000 REGULATION. respecting veterinarians authorisations to prescribe drugs SECTION II

Summary of Product Characteristics

Knowledge list Avian/Exotic Pharmacology and Commonly Used Drugs

SUMMARY OF PRODUCT CHARACTERISTICS. Pentoject, Pentobarbitone Sodium 200 mg/ml Solution for Injection

PRESS RELEASE COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Meeting of 12 to 14 October 2004

COMMISSION DELEGATED REGULATION (EU) /... of XXX

EPAR type II variation for Metacam

DISSOCIATIVE ANESTHESIA

COMMISSION. (Text with EEA relevance) (2009/712/EC)

Welcome to. Who Wants to be a Millionaire 50:50

Official Journal of the European Union L 280/5

SUMMARY OF PRODUCT CHARACTERISTICS

Committee on the Environment, Public Health and Food Safety

SUMMARY OF PRODUCT CHARACTERISTICS

V E T E R I N A R Y C O U N C I L O F I R E L A N D ETHICAL VETERINARY PRACTICE

SUMMARY OF PRODUCT CHARACTERISTICS

Council of the European Union Brussels, 17 September 2014 (OR. en) Mr Uwe CORSEPIUS, Secretary-General of the Council of the European Union

Guideline on quality data requirements for veterinary medicinal products intended for minor use or minor species (MUMS)/limited market

Opinion of the Committee for Medicinal Products for Veterinary Use pursuant to Article 30(3) of Regulation (EC) No 726/2004

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY

A New Advancement in Anesthesia. Your clear choice for induction.

Day 90 Labelling, PL LABELLING AND PACKAGE LEAFLET

(Non-legislative acts) REGULATIONS

Mitigating Pain in Livestock: What Options are Available

SUMMARY OF PRODUCT CHARACTERISTICS

1. ABOUT THE CONSULTATION

GUIDELINES FOR ANESTHESIA AND FORMULARIES

COUNCIL REGULATION (EEC) No 2377/90

N.C. A and T List of Approved Analgesics 1 of 5

COMMISSION DELEGATED REGULATION (EU)

T u l a n e U n i v e r s i t y I A C U C Guidelines for Rodent & Rabbit Anesthesia, Analgesia and Tranquilization & Euthanasia Methods

Dexmedetomidine and its Injectable Anesthetic-Pain Management Combinations

LIFE.2.B EUROPEAN UNION. Brussels, 14 November 2018 (OR. en) 2014/0255 (COD) PE-CONS 43/18 AGRILEG 102 VETER 52 CODEC 1149

COMMISSION DECISIONS. L 94/100 Official Journal of the European Union

Kennel Club Response to the Home Office s draft guidance on the operation of the Animals (Scientific Procedures) Act 1986 (ASPA) Consultation.

COMMISSION OF THE EUROPEAN COMMUNITIES. Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

Optometry Act, 1991 Loi de 1991 sur les optométristes

GUIDANCE FOR VETERINARY SURGEONS. Use of norethisterone for oestrus suppression in racing bitches in Great Britain

Table 2 - Medications and their ideal route of administration

2010 No AGRICULTURE, ENGLAND. The Animals and Animal Products (Import and Export) (England) (Amendment) Regulations 2010

European Public MRL assessment report (EPMAR)

Pain Management in Racing Greyhounds

The Animal Welfare Ordinance. 1988:539 Consolidated text (as last amended by SFS 2003:1124 of December 19, 2003)

This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents

SUMMARY OF PRODUCT CHARACTERISTICS

PROFESSIONAL PRACTICE STANDARD

This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents

PRESS RELEASE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

L 39/12 Official Journal of the European Union

Official Journal of the European Union

MINISTRY OF SOCIAL JUSTICE & EMPOWERMENT NOTIFICATION. New Delhi, the 15th December, 1998

Scientific Discussion post-authorisation update for Rheumocam extension X/007

Council of the European Union Brussels, 15 September 2014 (OR. en) Mr Uwe CORSEPIUS, Secretary-General of the Council of the European Union

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC FOR ANTIMICROBIAL PRODUCTS

DIRECTIVE 2010/63/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

Guidance Document. Veterinary Operating Instructions. Guidance re: Requirements for Authorising Veterinarians Notice.

Proposal for a Regulation on veterinary medicinal products

Draft ESVAC Vision and Strategy

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

ANNEXES. to the Proposal. for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL

Working for organic farming in Europe

Health Products Regulatory Authority

Official Journal of the European Union. (Acts whose publication is obligatory)

LARC FORMULARY ANESTHESIA AND ANALGESIA IN LABORATORY ANIMALS

Medicines for bees. Establishment of maximum residue limits. Principles for marketing authorisations

Irish Medicines Board

Regulated Control Scheme Control of Specified Substances 14 December 2017

1. ABOUT THE CONSULTATION

REGULATION (EC) No 854/2004 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 29 April 2004

(Text with EEA relevance)

MAXIMUM RESIDUE LIMITS FOR VETERINARY MEDICINAL PRODUCTS

Summary of Product Characteristics

Sales survey of Veterinary Medicinal Products containing Antimicrobials in France Volumes and estimated exposure of animals to antimicrobials

Guideline to Supplement to Codes of Practice Greyhound Euthanasia

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

THE CROATIAN PARLIAMENT. Pursuant to Article 88 of the Constitution of the Republic of Croatia, I hereby issue the DECISION

Maximum Residue Limits (MRLs) and Consumer safety. Presented by: Isaura Duarte, European Medicines Agency

CVMP strategy on antimicrobials

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Law on Special Measures Against Bovine Spongiform Encephalopathy (Law No. 70 of June 14, 2002)

COMMISSION IMPLEMENTING REGULATION (EU)

Transcription:

Using the Cascade and Essential List for Equidae Prof. Alistair Barr University of Bristol UK Practicing veterinary surgeons would like to have available to them the widest possible range of substances for use in the investigation and treatment of animals presented to them. Policy (and legislation) in this area seeks to balance that desire for availability against needs for 1. Safety 2. Quality 3. Efficacy 4. Protection of the investment of the developer of a medicine and the holder of the marketing authorisation Safety relates to that of.. 1. The animal 2. The operator 3. The consumer 4. The environment The mechanisms to achieve this are. 1. Requirement for marketing authorisation and processes that surround that (including MRLs) 2. Rules to specify the use of authorised VMPs where available 3. The ability to resort to the cascade under specified circumstances marketing authorisation requirement 1. Requirement for marketing authorisation and processes that surround that Articles 5 and 6.

marketing authorisation requirement 1. Requirement for marketing authorisation and processes that surround that Article 5 (1) No veterinary medicinal product may be placed on the market of a Member State unless a marketing authorisation has been granted issued by the competent authorities of that Member State in accordance with this Directive. 1. Requirement for marketing authorisation and processes that surround that Article 6 (1) A veterinary medicinal product may not be the subject of a marketing authorisation for the purpose of administering it to one or more food-producing species unless the pharmacologically active substances which it contains appear in es I, II or III to Regulation (EEC) No 2377/90. ie have established MRLs 1. Requirement for marketing authorisation and processes that surround that Article 6 (3) By way of derogation from paragraph 1, a veterinary medicinal product containing pharmacologically active substances not included in es I, II or III to Regulation (EEC) No 2377/90 may be authorised for particular animals of the equidae family that have been declared, in accordance with Commission Decisions 93/623/EEC and 2000/68/EC..as not being intended for slaughter for human consumption. Such veterinary medicinal products shall neither include active substances that appear in IV to Regulation (EEC) No 2377/90 nor be intended for use in the treatment of conditions, as detailed in the authorised Summary of Product Characteristics, for which a veterinary medicinal product is authorised for animals of the equidae family. - baseline use of authorised VMPs 2. Rules to specify the use of authorised VMPs where available Article 9 No veterinary medicinal product may be administered to animals unless the marketing authorisation has been issued,.. (Exemptions under the cascade in Articles 10 and 11) 3. The ability to resort to the cascade under specified circumstances Article 10 cascade for non-food animals Article 11 cascade for food animals Article 10 (1) cascade for non-food animals Member States shall take the necessary measures to ensure that, if there is no authorised medicinal product in a Member State for a condition affecting a non food-producing species, by way of exception, the veterinarian responsible may, under his/her direct personal responsibility and in particular to avoid causing unacceptable suffering treat the animals concerned with: (a) a veterinary medicinal product authorised for use in another animal species, or for another condition in the same species; or (b) if there is no product as referred to in point (a), either: (i) a medicinal product authorised for human use in the Member State concerned..or (ii) in accordance with specific national measures, a veterinary medicinal product authorised in another Member State.or (c) if there is no product as referred to in subparagraph (b) and within the limits of the law of the Member State concerned, of a veterinary medicinal product prepared extemporaneously by a person authorised to do so.

Article 10 (2) cascade for non-food horses By way of derogation from Article 11, the provisions of paragraph 1 of this Article shall also apply to the treatment by a veterinarian of an animal belonging to the equidae family provided that it has been declared, in accordance with Commission Decisions 93/623/EEC and 2000/68/EC, as not being intended for slaughter for human consumption. Article 10 (3) essential substances list for FOOD horses By way of derogation from Article 11,.the Commission shall establish a list of substances essential for the treatment of equidae.and for which the withdrawal period shall be not less than six months according to the control mechanisms laid down in Decisions 93/623/EEC and 2000/68/EC. Article 11 (1) cascade for food animals Member States shall take the necessary measures to ensure that, if there is no authorised veterinary medicinal product in a Member State for a condition affecting a food-producing species, by way of exception, the veterinarian responsible may, under his direct personal responsibility and in particular to avoid causing unacceptable suffering, treat the animals concerned on a particular holding with: (a) a veterinary medicinal product authorised in the Member State concerned for use with another animal species, or for another condition in the same species; or (b) if there is no product as referred to in point (a), either: (i) a medicinal product for human use authorised in the Member State concerned in accordance with Directive 2001/83/EC.or (ii) a veterinary medicinal product authorised in another Member State in accordance with this Directive for use in the same species or in another food-producing species for the condition in question or for another condition; or (c) if there is no product as referred to in subparagraph (b), and within the limits of the law of the Member State concerned, a veterinary medicinal product prepared extemporaneously by a person authorised to do so... BUT Article 11 (2) cascade for food animals Paragraph 1 shall apply provided that pharmacologically active substances included in the medicinal product are listed in I, II or III to Regulation (EEC) No 2377/90, and that the veterinarian responsible specifies an appropriate withdrawal period. Article 11 (4) cascade for food animals When a veterinarian has recourse to the provisions of paragraphs 1 and 2 of this Article 10, he shall keep adequate records of the date of examination of the animals, details of the owner, the number of animals treated, the diagnosis, the medicinal products prescribed, the doses administered, the duration of treatment and the withdrawal periods recommended, and shall make these records available for inspection by the competent authorities for a period of at least five years. Article 10 (3) essential substances list for FOOD horses The list of substances essential for the treatment of equidae is now contained in..

Article 2 Essential substances may be used,. - for the specific disease conditions, treatment needs or zootechnical purposes specified in the, - where no medicinal product authorised for equidae or referred to in Article 11 of would yield equally satisfactory results in terms of - successfully treating the animal, - avoiding unnecessary suffering for the animal, or - ensuring the safety of those treating the animal. Article 3 1. Essential substances may be used only in accordance with Article 10(1) of (general cascade provisions) 2. The details of a treatment with essential substances must be recorded in accordance with the instructions laid down in Section IX of the identification document for equidae set out in Decisions 93/623/EC and 2000/68/EC. Article 5 1. The European Medicines Agency shall, at the request of the Commission, ensure that the Committee for Medicinal Products for Veterinary Use carries out a scientific evaluation of any draft amendment to the list set out in the. Within 210 days of receiving such a request, the European Medicines Agency shall deliver an opinion to the Commission on the scientific suitability of the amendment. Where appropriate, the European Food Safety Authority shall also be consulted. 2. When Member States or veterinary professional associations ask the Commission to amend the list set out in the they shall duly substantiate their request and include any relevant scientific data available. Anaesthetics, analgesics and substances used in association with anaesthesia - Sedation and premedication (and antagonism) Acepromazine Atipamezole Diazepam Midazolam Naloxone Propofol Sarmazenil Tiletamine Zolazepam Hypotension or respiratory stimulation during anaesthesia Dobutamine Dopamine Ephedrine Glycopyrrolate Noradrenaline (norepinephrine) Analgesia Buprenorphine Fentanyl Morphine Pethidine Muscle relaxants and associated substances Atracurium Edrophonium Guaifenesin Inhalation anaesthetics Sevoflurane Local anaesthetics Bupivacaine Oxybuprocaine Prilocaine

Cardiovascular medicines Digoxin Quinidine sulphate and quinidine gluconate Procainamide Propanolol Convulsions Phenytoin Primidone Gastrointestinal agents Bethanechol Dioctyl sodium sulfosuccinate Metoclopramide Propantheline bromide Rhabdomyolysis Dantrolene sodium Antimicrobial - Klebsiella ssp. infections Ticarcillin - Rhodococcus equi infections Azithromycin Rifampicin - Septic arthritis Amikacin Respiratory medicines Ambroxol Ipratropium bromide Oxymetazolin Antiprotozoal agents Isometamidium Pyrimethamine Ophthalmic medicines - Ocular ulcers Acyclovir Idoxuridine Glaucoma Phenylephrine Tropicamide Dorzolamide Latanoprost Timolol maleate Cyclosporin A Ketorolac Ofloxacin Fluoresceine Rose Bengal Hydroxypropyl methylcellulose Hyperlipaemia Insulin Fungal infections Griseofulvin Ketoconazole Miconazole Nystatin Miscellaneous Chondroitin sulphate Domperidone Hydroxyethylstarch Imipramine Thyrotropin releasing hormone Barium sulphate Iohexol Iopamidol The cascade and (in the context of food horses) the essential substances list are vital enabling mechanisms for veterinary surgeons to allow them to investigate and treat animals where there are the inevitable gaps in the list of authorised VMPs The constraints imposed are a balance and whether that balance is correct depends very much on where you are looking from Hopefully the perspectives of the vet and the animal will always coincide. Veterinary surgeons also need to be cognisant of their responsibilities to consumers of food, the environment and the pharmaceutical industry s need for return on investment. The current balance is workable but not perfect it will hopefully continue to progress!